Patents by Inventor Abdelmalik Slassi

Abdelmalik Slassi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS
    Publication number: 20100016403
    Abstract: Compounds of Formula I are useful for the treatment of anxiety disorders such as generalized anxiety disorder (GAD), panic attack, post traumatic stress disorder (PTSD), obsessive compulsive disorder (OCD) and social phobias. wherein: A is chosen from: aryl or heteroaryl, A being optionally substituted with up to 5 independently-selected groups R8; R1 is chosen from: alkyl or haloalkyl; R2 is chosen from: H, C(O)R6, C(O)OR6, SO2R6 or C(O)NR6R7; R3, R4 and R5 are independently chosen from: H or alkyl; R6 and R7 are independently chosen from: H or alkyl; and R8 is chosen from: OH, CN, halo, alkyl, alkoxy, haloalkyl, haloalkoxy, C(O)R6, C(O)OR6, SO2R6 or C(O)NR6R7.
    Type: Application
    Filed: December 14, 2007
    Publication date: January 21, 2010
    Inventors: Guy Higgins, Abdelmalik Slassi, Methvin Isaac
  • Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
    Publication number: 20090275578
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: August 12, 2005
    Publication date: November 5, 2009
    Applicants: AstraZeneca AB, NPS PHARMACEUTICALS, INC
    Inventors: Joshua Clayton, Fupeng Ma, Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Ian Egle, James Empfield, Methvin Isaac, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • Additional heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
    Patent number: 7585881
    Abstract: The present invention relates to new compounds of formula I, to pharmaceutical formulations containing the compounds, and to the use of the compounds in the prevention and/or treatment of mGluR5 receptor-mediated disorders.
    Type: Grant
    Filed: February 9, 2005
    Date of Patent: September 8, 2009
    Assignee: AstraZeneca AB
    Inventors: Louise Edwards, Methvin Isaac, Martin Johansson, Annika Kers, Johan Malmberg, Donald McLeod, Alexander Mindis, Karin Staaf, Abdelmalik Slassi, Tomislav Stefanac, Thomas Stormann, David Wensbo, Tau Xin, Jalaj Arora
  • Fused heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
    Patent number: 7576077
    Abstract: The present invention is directed to compounds of formula I: wherein X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, R1, R2, R3, R4, and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: August 18, 2009
    Assignee: Astrazeneca AB
    Inventors: David Wensbo, Martin Johansson, Alexander Minidis, Karin Staaf, Annika Kers, Louise Edwards, Methvin Isaac, Tom Stefanac, Abdelmalik Slassi, Don McLeod, Tao Xin
  • Bicyclic Benzimidazole Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
    Publication number: 20090192169
    Abstract: Compounds of Formula I: wherein A, B, D, L, R1, R2, R3, R4, m, and n are as defined for Formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: March 29, 2007
    Publication date: July 30, 2009
    Inventors: Ian Egle, Methvin Isaac, Rebecca Urbanek, Frances M. McLaren, Sally B. Walsh, Gary B. Steelman, Dean G. Brown, David Nugiel, Deborah W. Chen, Abdelmalik Slassi, Fupeng Ma
  • Metabotropic Glutamate Receptor-Potentiating Isoindolones
    Publication number: 20090149505
    Abstract: Compounds of Formula I: wherein R1, R2, R3, R4, R5, R6 and R7 are as defined in the description, processes for the preparing such compounds, new intermediates employed in their preparation, pharmaceutical compositions containing the compounds, and uses of the compounds in therapy.
    Type: Application
    Filed: February 6, 2007
    Publication date: June 11, 2009
    Applicant: AstraZeneca AB
    Inventors: James R. Empfield, James J. Folmer, James R. Arnold, Joshua Clayton, Abdelmalik Slassi, Methvin Isaac, Ian Egle, Fupeng Ma
  • New compounds 067
    Publication number: 20090131454
    Abstract: The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.
    Type: Application
    Filed: October 17, 2008
    Publication date: May 21, 2009
    Applicant: AstraZeneca AB
    Inventors: Erwan Arzel, Louise Edwards, Methvin Isaac, Donald A. McLeod, Abdelmalik Slassi, Tao Xin
  • SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
    Publication number: 20090124578
    Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
    Type: Application
    Filed: January 13, 2009
    Publication date: May 14, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Ian EGLE, Babu Joseph, Abdelmalik Slassi, Methvin Isaac, Fupeng Ma, Joshua Clayton
  • 1,2,4-TRIAZOLE ETHER DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111857
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Peter DOVE, Kenneth Granberg, Methvin Isaac, Mats Nagard, Abdelmalik Slassi
  • SUBSTITUTED ISOINDOLONES AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS
    Publication number: 20090111830
    Abstract: The present invention is directed to compounds of formula I: wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: February 15, 2006
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Bradford Van Wagenen, Radhakrishnan Ukkiramapandian, Joshua Clayton, Ian Egle, James R. Empfield, Methvin Isaac, Fupeng Ma, Abdelmalik Slassi, Gary Steelman, Rebecca Urbanek, Sally Walsh
  • 1,2,4-TRIAZOLE CARBOXYLIC ACID DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111811
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Kenneth GRANBERG, Abdelmalik Slassi, Tomislav Stefanac, Andreas Wallberg
  • AMIDE LINKED HETEROAROMATIC DERIVATIVES AS MODULATORS OF MGLUR5
    Publication number: 20090111824
    Abstract: The present invention is directed to novel compounds, to a process for their preparation, their use in therapy and pharmaceutical compositions comprising the novel compounds.
    Type: Application
    Filed: October 24, 2008
    Publication date: April 30, 2009
    Applicant: AstraZeneca AB
    Inventors: Emma Bratt, Kenneth Granberg, Methvin Isaac, Mats Nagard, Abdelmalik Slassi
  • Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
    Publication number: 20090069340
    Abstract: Compounds of Formula (I), wherein R1, R2, R3, R4, R5, R6, X, and n are as defined for Formula (I) in the description, processes for the preparation of the compounds and new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and the use of the compounds in the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction.
    Type: Application
    Filed: December 22, 2005
    Publication date: March 12, 2009
    Applicant: AstraZeneca AB
    Inventors: Michael Balestra, Heather Bunting, Deborah Chen, Ian Egle, Janet Forst, Jennifer Frey, Methvin Isaac, Fupeng Ma, David Nugiel, Abdelmalik Slassi, Gary Steelman, Guang-Ri Sun, Babu Sundar, Radhakrishnan Ukkiramapandian, Rebecca Urbanek, Sally Walsh
  • Use
    Publication number: 20090054491
    Abstract: The present invention relates to the use of compounds of formula II for the treatment or prevention of obesity.
    Type: Application
    Filed: June 19, 2006
    Publication date: February 26, 2009
    Applicant: AstraZeneca AB
    Inventors: Louise Edwards, Methvin Isaac, Abdelmalik Slassi, Mats Nagard, Leonard Storlien, David Morgan
  • Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
    Patent number: 7485722
    Abstract: Compounds in accord with Formula I: wherein R1, L, A, B, D, E, m, n, x and y are as defined in the description, processes for the preparation of such compounds and to new intermediates employed in the preparation thereof, pharmaceutical compositions containing such compounds, and the use of such compounds in therapy and for the treatment of diseases mentioned in the specification.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: February 3, 2009
    Assignee: AstraZeneca AB
    Inventors: Ian Egle, Babu Joseph, Abdelmalik Slassi, Methvin Isaac, Fupeng Ma, Joshua Clayton
  • Piperazines and Piperidines as Mglur5 Potentiators
    Publication number: 20090023711
    Abstract: Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: wherein Ar1, Ar2, A, X, Y, m, n and R1, R2, R3, R4 and R5 are as described in the specification, processes for their preparation, pharmaceutical formulations comprising them and their use in therapy, particularly in the therapy of neurological and psychiatric disorders associated with glutamate dysfunction.
    Type: Application
    Filed: January 5, 2007
    Publication date: January 22, 2009
    Applicant: AstraZeneca AB
    Inventors: Abdelmalik Slassi, Methvin Isaac, Jalaj Arora, Dean Brown
  • Compounds for the treatment of neurological, psychiatric or pain disorders
    Patent number: 7476684
    Abstract: The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: January 13, 2009
    Assignee: AstraZeneca AB
    Inventors: Alexander Minidis, David Wensbo, Methvin Isaac, Abdelmalik Slassi, Jalaj Arora, Tao Xin, Louise Edwards, Caroline Eriksson, Veronica Profir, Per-Olov Bergstrom
  • Oxazolidinone Compounds and Their Use as Metabotropic Glutamate Receptor Potentiators
    Publication number: 20090012089
    Abstract: The present invention is directed to compounds of Formula I: Wherein R1, R2, Y, m and n are further defined in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.
    Type: Application
    Filed: December 6, 2006
    Publication date: January 8, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Abdelmalik Slassi, Babu Joseph, Fupeng Ma, Ian Egle, Joshua Clayton, Methvin Isaac, Krzysztof Swierczek
  • Fluorinated Compounds
    Publication number: 20090005433
    Abstract: Compounds of Formula I are useful in the treatment of epilepsy, neuropathic pain, acute and chronic inflammatory pain, migraine, tardive dyskinesia and other related CNS disorders. wherein: A and R1 to R8 are defined in the specification.
    Type: Application
    Filed: December 14, 2006
    Publication date: January 1, 2009
    Inventors: Guy A Higgins, Methvin Issac, Abdelmalik Slassi, Tao Xin
  • Tricyclic Benzimidazoles and Their Use as Metabotropic Glutamate Receptor Modulators
    Publication number: 20080318999
    Abstract: The invention provides for a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein R1, R2, R3, A, B, D, m, n, x, and y are defined as described in the specification. The invention additionally provides a pharmaceutically composition comprising the compound of formula I, together with a method of using the same to treat or prevent neurological and psychiatric disorders. The compounds are useful in therapy related to the treatment or prevention of mGluR2 receptor-mediated disorders.
    Type: Application
    Filed: July 21, 2006
    Publication date: December 25, 2008
    Inventors: Methvin Isaac, Abdelmalik Slassi, Ian Egle, Fupeng Ma